´ó·¢ÁùºÏ²Ê

Facts, figures and industry data

Facts, figures and industry data

Headline pharmaceutical industry statistics

The figures below provide a snapshot of key biopharmaceutical sector statistics relating to the UK’s economy and health systems. Sub-national statistics can be found via the ´ó·¢ÁùºÏ²Ê’s interactive . International comparisons are available in several of the source documents and within the Government’s Life Sciences Competitiveness Indicators . Statistics on the economic and health system benefits which can be delivered through a supportive policy environment are available in the ´ó·¢ÁùºÏ²Ê’s manifesto.ÌýÌý

Economic statistics

£17.6bn

direct Gross Value Added (GVA) [1]

£45bn

R&D spillovers [2]

£9bn

investment in UK R&D (more than UKRI’s entire annual budget) [3]

£26.1bn

exports [4]

126,000

jobs [5]

£46.7bn

turnover [6]

Over 3,000

manufacturing and research sites combined [6]

£355m

revenue [7]

£28.6m

cost savings for the NHS in England through industry clinical trials in 2018/19 [7]

Health system statistics

9%

Amount the UK invests of overall healthcare spending on medicines – a significantly lower proportion than other advanced healthcare systems such as the United States (14%), France (15%), Germany (17%) and Japan (17%) [8]

42,088

patients recruited to industry clinical trials in 2022/23 (increasing from 36,722 in 2021/22, but below pre-pandemic levels of 58,048 in 2017/18) [9]

411

industry clinical trials initiated in the UK in 2022 (increasing from 394 trials in 2021, but below the 2015 peak of 690 trials) [10]

70%

UK average uptake of medicines launched between 2018-22 is 70% of the average uptake of comparator countries three years after launch [11]. Across the UK, variation persists. For example, patients in Derby ICS are 3x less likely to access new NICE-approved medicines compared to Norfolk or Surrey ICSs [12]


References:

[1] ONS, ‘Regional gross value added (balanced) by industry: all ITL regions’, 2021. Methodology available at:

[2] ´ó·¢ÁùºÏ²Ê, ‘Life Sciences Superpower’, June 2022, available at www.abpi.org.uk/publications/abpi-life-sciences-superpower-report/

[3] ONS, ‘Business Enterprise Research and Development statistics 2022’ available at

[4] Office for National Statistics, ‘Trade in goods: country-by-commodity exports’, accessed 17 July 2024, available at Ìý

[5] ONS, ‘Industry Census Data 2021’, available at: (methodology available at )

[6] OLS, ‘Bioscience and health technology sector statistics 2021 to 2022’, available at: Ìý

[7] NIHR, ‘Impact and value of the NIHR Clinical Research Network 2019’, accessed January 2024, available at

[8] The King’s Fund, ‘How does the NHS compare to the health care systems of other countries?’, June 2023, available at:

[9] Number of participants recruited to industry research studies in

the UK per year, as reported by the NIHR CRN, NRS, HCRW, and NICRNÌý(2017/18-2022/23)

[10] Clarivate data, included in the ´ó·¢ÁùºÏ²Ê’s report: ‘Getting back on track: Restoring the UK’s global position in industry clinical trials’, November 2023, available at www.abpi.org.uk/publications/getting-back-on-track-restoring-the-uk-s-global-position-in-industry-clinical-trials/

[11] Uptake ratios three years post-reimbursement (n=36 medicines), Office for Life Sciences, ‘Life Sciences Competitiveness Indicators 2024’ available at: Ìý

[12] Local Uptake of NICE Approved Medicines in England and Wales, A Summary ofÌýInsights – June 2022, IQVIA report, commissioned by the ´ó·¢ÁùºÏ²Ê

Industry data